| Model Number |
3000 |
| Medical Device Problem Codes |
Calcified (1077); Insufficient Device Problem Information (3190)
|
| Health Effect - Clinical Codes |
Dyspnea (1816); Insufficient Information (4580)
|
| Date of Event |
07/27/2023
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
Surgical/percutaneous intervention is indicated or performed, or harm occurred, due to the device, or there is a device malfunction that could cause or contribute to a serious injury.This event is considered a serious injury.The investigation is still in progress.Therefore, a conclusion has yet to be established.A supplemental report will be submitted, accordingly upon investigation completion.Edwards will continue to review and monitor all reported events.Trends are monitored on a monthly basis.And if action is required, appropriate investigation will be performed.
|
| |
|
Event or Problem Description
|
|
It was learned through implant patient registry, that a patient with a 25mm 3000 aortic valve was explanted.After an implant duration of (b)(6) years, (b)(6) months, due to unknown reasons.The explanted valve was replaced with a 23mm 11500a aortic valve.Edwards lifesciences maintains an implant patient registry.This registry is a patient tracking mechanism for serialized edwards implantable devices (bioprosthetic heart valves and annuloplasty rings), rather than a true post-market surveillance registry.Through the registry, edwards is notified when these devices are implanted.In addition, patient and/or device status may be reported to the registry via the implantation data cards.The information is received from various sources (e.G.Surgeon, hospital, and patient family members), and is not received in the form of a conventional "customer complaint".The information reported may or may not be related to the edwards device.
|
| |
|
Additional Manufacturer Narrative
|
|
Calcific degeneration is a common cause of bioprosthetic heart valve failures.Many factors contribute to the onset and propagation of calcification.These include patient factors (age, disease state, pharmacological intervention, etc.), mechanical stress related to the valve's hemodynamic performance, and glutaraldehyde fixation of tissue.Of these, the fixation process is a relatively minor contributor to calcification for edwards' tissue valves due to anti-calcification treatments during manufacturing.Though numerous studies have been conducted on preventive calcification strategies in bioprosthetic heart valves, the causes of calcification are not fully understood and there are still no mechanisms or medical therapies which fully prevent bioprostheses from calcifying.Calcification is most commonly related to patient factors and is not usually an indication of a device malfunction.The most likely cause is patient factors, including coronary artery disease (cad) and hyperlipidemia (hld).
|
| |
|
Additional Manufacturer Narrative
|
|
The device history record (dhr) review was completed and this device passed all manufacturing and sterilization inspections prior to release for distribution.There were no issues identified that would have impacted this event.
|
| |
|
Event or Problem Description
|
|
It was learned through implant patient registry and later through medical records that a patient with a 25mm 3000 aortic valve was explanted after an implant duration of 6 years, 7 months due to calcified leaflets.The patient presented with shortness of breath.The explanted valve was replaced with a 23mm 11500a aortic valve.The patient was stable and transferred to icu post procedure.The patient was discharged on pod #6.The pathology report confirmed diffusely calcified leaflets.
|
| |
|
Search Alerts/Recalls
|